Table 2.
Therapeutic effects in the two groups
| Therapeutic effecta | After induction therapy (n = 118) |
After concurrent radiochemotherapy (n = 117)b |
3 months after the treatment (n = 117) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal lesions (%) | Lymph node lesions (%) | Total(%)(nasopharyngeal and lymph node lesions) | ||||||||
| NPF group (n = 58) | DPF group (n = 60) | NPF group (n = 58) | DPF group (n = 60) | NPF group (n = 58) | DPF group (n = 60) | NPF group (n = 58) | DPF group (n = 59) | NPF group (n = 58) | DPF group (n = 59) | |
| CR | 2(3.4) | 0(0) | 5(8.6) | 1(1.7) | 2(3.4) | 0(0) | 39(67.2) | 38(64.4) | 51(87.9) | 50(84.7) |
| PR | 33(56.9) | 31(51.7) | 42(72.4) | 35(58.3) | 39(67.2) | 37(61.7) | 19(32.8) | 21(35.6) | 7(12.1) | 9(15.3) |
| SD | 23(39.7) | 29(48.3) | 11(19.0) | 24(40.0) | 17(29.3) | 22(36.7) | 0(0) | 0(0) | 0(0) | 0(0) |
| PD | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 1(1.7) | 0(0) | 0(0) | 0(0) | 0(0) |
| P | 0.446 | 0.036 | 0.143 | 0.499 | 0.409 | |||||
aCR Complete remission, PR Partial remission, SD Stable disease, PD Progressive disease
b After induction therapy, 1 patient in the DPF group showed distant metastasis and withdrew from the study